News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

XIGEN Appoints Didier Coquoz, Pharm.D., Ph.,D. As Chief Executive Officer



10/19/2005 5:08:41 PM

Xigen S.A., a Swiss biotechnology company engaged in research and development of intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer, announced the appointment of Didier Coquoz, Pharm. D., Ph.D. as Chief Executive Officer. Dr. Coquoz was most recently Vice-President Research and Development of H3 Pharma in Montreal, Canada.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES